-- Robert Preidt
TUESDAY, Oct. 5 (HealthDay News) -- Adding a new vaccine to
standard therapy extended survival for people with the most deadly
type of brain cancer in a small study.
Researchers from Duke University Medical Center and the
University of Texas M.D. Anderson Cancer Center report that the
case-control study included 35 patients newly diagnosed with the
brain cancer, known as glioblastoma (GBM). The patients were
divided into two groups: Both received surgery, radiation and the
chemotherapy drug temozolomide, but one group of 18 patients also
began receiving injections of the new vaccine one month after
completing radiation and continued to receive the vaccine as long
as it appeared to be effective.
Median survival time for those in the vaccine group was 26
months, compared with 15 months for the control group.
Progression-free survival was 14.2 months in the vaccine group,
compared to 6.3 months in the control group.
The vaccine appeared to stimulate an immune response in
approximately half of the patients who received it, suggesting such
responses were linked to increased survival time, "but the numbers
are so small that we cannot conclude this with any degree of
certainty," Dr. Amy Heimberger, co-lead investigator from M.D.
Anderson, said in a news release from Duke.
The vaccine knocks out a growth factor associated with the most
aggressive form of the brain cancer.
"About a third of all glioblastomas are fueled by a very aggressive cancer gene, called EGFRvIII; these tumors are the 'worst of the worst,'" Dr. John Sampson, a professor of neurosurgery at Duke University Medical Center, said in the news release.
The presence of EGFRvIII allows cancer cells to multiply out of
control, seeding new tumors throughout the brain, the researchers
explained. Even with advances in chemotherapy and radiation,
prognosis for patients with glioblastoma is poor, with an average
survival time of one year after diagnosis.
About 10,000 new cases of glioblastoma appear in the United
States every year.
"Our study showed that the vaccine eliminated all of the cancer cells carrying this marker in all but one of our study participants," study senior author Dr. Darell D. Bigner, director of the Preston Robert Tisch Brain Tumor Center, said in the news release. (Bigner is one of three scientists who discovered the gene variant EGFRvIII.)
The vaccine is known variously as CDX-110 by Celldex
Therapeutics or PF-04948568 by Pfizer.
The study appears online Oct.4 in the
Journal of Clinical Oncology.
Drs. Bigner, Heimberger and Sampson, along with Duke University
and M.D. Anderson, have potential conflicts of interest from
consulting agreements, stock options and possible licensing fees,
according to background material for the study. Duke and M.D.
Anderson have plans in place to manage potential conflict of
interest, the statement said.
The U.S. National Cancer Institute has more about
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.